

## ColonSentry®

The Best Test for Colorectal Cancer is the One That Gets Done



#### THE CHALLENGE

You can't find colorectal cancer (CRC) early in patients who refuse to be screened. Unfortunately, 33% of average risk patients eligible for colorectal cancer screening are non-compliant with any form of CRC screening including imaging and stool-based tests.

#### THE COLONSENTRY SOLUTION

- ColonSentry is a 7-gene, blood-based biomarker panel that can stratify non-compliant patients according to their current, relative risk of having colorectal cancer in an average-risk population.(1-2)
- The ColonSentry test has a 95% in-office compliance rate that motivates patients to comply with CRC screening.
- Data shows that patients with elevated ColonSentry scores are likely to move forward with Colonoscopy.

### THE SCIENCE BEHIND OUR TEST

- ColonSentry<sup>®</sup> uses StageZero's proprietary Sentinel Principle technology, which is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body.
- ColonSentry uses mRNA gene expression to create a genetic signature by which a patient's risk is stratified.
- The ColonSentry test was Validated in a study of 10,000 patients in North America. (1-2)
- Negative predictive value of ColonSentry is 99.6% (1-2)
- ColonSentry has been utilized on over 100,000 patients in the United States.

#### WHY USE THIS TEST IN MY PRACTICE?

- Get your eligible, average-risk patients who are non-compliant screened for CRC.
- When CRC is found early, the five-year survival rate is 90% (3) Found late, the five-year survival rate drops to 14%.(3)
- Young adults with colon cancer have a statistically higher risk of advanced disease at the time of operation.(7)

### **PATIENT SELECTION CRITERIA**

• For use on men and women age 45 and over who have yet to comply with Colorectal Cancer Screening.

Contact Us Today to Get Started 1-855-420-7140

clientrelations@stagezerols.com



## **ColonSentry**®

The Best Test for Colorectal Cancer is the One That Gets Done

X JIAGE		
	Colons	Sentry®
LIFE SCIENCES LABO	RATORY R	ESULTS
Name: Phone #: Patient ID #: _ Collection Time: Specimen ID:	Requesting Provider	
t <u>e</u>		
0 Fasting Status: Gender Birthdate: Age: Collection Date: Report Type:		
Height: Weight: BMI: Prev. BMI: 0 Received Date: Report Date:	Client ID:	
±		
103		
The notiont has an Elevated risk		
of having colorectal cancer 2X than the		
average risk <sup>‡</sup> .		
98		
97	6 7 8	9 10
± Average risk of CRC is 0.7% 2X Patient's		
Current Risk		
Tast Description		
rest Description	Gene Expre	ssion
Test results are reported with a 95% CI (Confidence Interval).	Gene Expre	ssion ycle Threshold
Test cost cost profit Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population.	Gene Expre Gene Cy ANXA3* (ÅCt)	ssion ycle Threshold 1.9
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population.	Gene         Cy           Δεne         Cy           ΑΝΧΑ3* (ΔCt)         CLEC4D* (ΔCt)	ssion ycle Threshold 1.9 2.5
Test results are reported with a 95% CI (Confidence Interval). The CoinSenty® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) reliative to the current risk in an average risk population.	Gene Expre Gene Cy ANXA3* (ÅCt) CLEC4D* (ÅCt)	ssion ycle Threshold 1.9 2.5
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population.	Gene Expre Gene Cy ANXA3* (ÅCt) CLEC4D* (ÅCt) TNFAIP6* (ÅCt)	SSION ycle Threshold 1.9 2.5 1.8
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. Clinical Recommendations If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy, Average risk scores for the ColonSentry® test do not rule	Gene         Expre           Gene         Cy           ANXA3* (&Ct)         CLEC4D* (&Ct)           TNFAIP6* (&Ct)         LMNB1* (&Ct)	ssion yde Threshold 1.9 2.5 1.8 1.8
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. Clinical Recommendations If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught early, colon cancer is both treatable and beatable.	Gene Expre Gene ANXA3* (ÅCI) CLEC4D* (ÅCI) TNFAIP6* (ÅCI) LMNB1* (ÅCI)	<b>SSION</b> role Threshold 1.9 2.5 1.8 1.8 0.9
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. Clinical Recommendations If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught early, colon cancer is both treatable and beatable. Average Risk: recommendation* for CIIT-DNA, flexible signoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for colonoscopy.	Gene         Expre           Gene         Cr           ANXA3* (&Cr)         CLEC4D* (&Cr)           TNFAIP6* (&Cr)         LMNB1* (&Cr)           PRRG4* (&Cr)         VNN1* (&Cr)	ssion vele Threshold 1.9 2.5 1.8 1.8 0.9 1.5
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. Clinical Recommendations If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught early, colon cancer is both treatable and beatable. Average Risk: recommendation* for CIT. FIT-DNA, flexible signoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for colonoscopy. * Somering for Colonectal Cancer US Preventive Services Task Force Recommendation Statemert. JAMA Jun 21, 2016, 315(23):2564-2575	Gene         Expre           Gene         C           ANXA3* (ÅCt)         C           CLEC4D* (ÅCt)         T           TNFAIP6* (ÅCt)         LMNB1* (ÅCt)           PRRG4* (ÅCt)         VNN1* (ÅCt)	ssion vele Threshold 1.9 2.5 1.8 1.8 0.9 1.5 22.5 2
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. <b>Clinical Recommendation</b> If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught early, colon cancer is both treatable and beatable. Average Risk: recommendation* for FIT, FIT-DNA, flexible sigmoidoscopy, CT colonography, or colonoscopy. Levated Risk: recommendation* for colonoscopy. * Servering for Coloncedu Cancer US Preventive Services Tals Fore Recommendation Statemert. JAMA Jan 21, 2016; 315(23):2964-2875	Gens         C           ANXA3* (ÅC)         CLEC4D* (ÅC)           CLEC4D* (ÅC)         CLEC4D* (ÅC)           INNA1* (ÅC)         PRRG4* (ÅC)           VNN1* (ÅC)         IL/2R (Ci)           */Ittento with structure (AC)         */Ittento with structure (AC)	ssion vois Threshold 1.9 2.5 1.8 1.8 0.9 1.5 24.5
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. <b>Clinical Recommendations</b> If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught test, colon cancer is both treatable and beatable. Average Risk: recommendation* for FIT, FIT-DNA, flexible sigmoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for colonoscopy. ** Streenge for Covidual Cancer US Preventive Sarvices Task Force Recommendation Statement. JAMA Jun 21, 2016; 315(22):2564-2575 <b>What to don next?</b>	Gens         C           ANXA3* (ÅC)         CLEC4D* (ÅC)           CLEC4D* (ÅC)         CLEC4D* (ÅC)           INNA1* (ÅC)         PRRG4* (ÅC)           VNN1* (ÅC)         ILIZRB (C)           * Difference with respect to         * Difference with respect to	ssion vois Threshold 1.9 2.5 1.8 1.8 0.9 1.5 24.5 1288
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. Clinical Recommendations If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught early, colon cancer is both treatable and bestable. Average Risk: recommendation* for FIT, FIT-DNA, flexible sigmoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for forT, FIT-DNA, flexible sigmoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for for Consocopy. ** Soreening for Colorectal Cancer US Preventive Services Task Force Recommendation Statemert. JAMA Jun 21, 2016; 315(23):2564-2575 Matt to do next? According to USPSTP*, an average risk patient is a man or woman who is at least 50 years old, is asymptomatic for CC colorectal polysis, colorectal advections, CRC or inflammatory bovel disease, and does not have a first degree relative	Gene Expre Gens C ANXA3* (AC) CLEC4D* (AC) TNFAIP6* (AC) LMNB1* (AC) PRRG4* (AC) VNN1* (AC) LLZRB (C) * Difference with respect to RC, has no personal hit presence	ssion           role Threshold           1.9           2.5           1.8           1.8           0.9           1.5           24.5           ILZRB           story of benign e of conditions
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. Clinical Recommendations If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught early, colon cancer is both treatable and bestable. Average Risk: recommendation* for FIT, FIT-DNA, fixelible sigmoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for colonoscopy. * Streeming for Colorectal Cancer US Preventes Services Task Force Recommendation Statemert. JAMA Jun 21, 2016, 315(23):2564-2575 What to do next? According to USPSTF*, an average risk patient is a man or woman who is at least 50 years old, is asymptomatic for C colorectal Jobys, colorectal advections. CRC or inflammatory bowed disease, and does not have a first degree relative such as pancreatic cancer, systemic sderosts or CLL might affect the risk score. Screening for colorectal colorectal colorectal polyne through defection and treatment of advectance cancer and detection	Gene Expre cense ANXA3* (ACI) CLEC4D* (ACI) INFAIPS* (ACI) IMNB1* (ACI) PRRC4* (ACI) VNN1* (ACI) IL2RB (CI) * 01/liferince with respect to RC, has no personal the presence and removal of advance	ssion clip Threshold 1.9 2.5 1.8 1.8 0.9 1.5 24.5 L2R8 story of benign e of conditions
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population.  Clinical Recommendations If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test measures average Risk: recommendation* for FIT, FIT-DNA, flexible sigmoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for FIT, FIT-DNA, flexible sigmoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for colonoscopy.  ** Streening for Colorectal adenomas. CRC or inflammatory bowel disease, and does not have a first degree relative such as pancreatic cancer, velase mechanisms contributes to a reduction in mortality surfavora, almough it sinkloy is full degree in the risk score. Screening for colorectal adenomas. CRC or inflammatory bowel disease, and does not have a first degree relative such as pancreatic cancer, system semetality through detection and treatment of early-stage cancer and detection The degree to which each of these mechanisms contributes to a reduction in mortality surfavora, mathough it is likely cancer mortality during the 10 years after initial screening comes from the detection and removal of early-stage cancer ************************************	Gene Expre Gens C ANXA3* (AC) CLEC4D* (AC) TNFAIP6* (AC) LMNB1* (AC) PRRG4* (AC) VNN1* (AC) LIZRB (C) * Ülference with respect to and removal of dedono: RC, has no personal hill with CRC. The presence and removal of dedono:	ssion (de Threshold 1.9 2.5 1.8 1.8 0.9 1.5 24.5 uzas story of benign e of conditions natious polyps. in in concretal besary step in
Test results are reported with a 95% CI (Confidence Interval). The ColonSentry® test measures the expression of 7 gene biomarkers in whole blood to help determine a patient's Current Risk for having colorectal cancer (CRC) relative to the current risk in an average risk population. <b>Clinical Recommendations</b> If the results indicate that the patient's current risk is elevated (2X or more), the patient should be referred for further evaluation with procedures such as colonoscopy. Average risk scores for the ColonSentry® test do not rule out colon cancer. When caught early, colon cancer is both treatable and beatable. Average Risk: recommendation** for FIT, FIT-DNA, flexible sigmoidoscopy, CT colonography, or colonoscopy. Elevated Risk: recommendation* for colonoscopy. ** severage for colorectal cancer Us Preventive Services Task Force Recommendation Statement. JAMA Jun 21, 2016; 315(22);2564-2575 <b>What to don cancer</b> . Screening for colorectal adenomas. CRC or inflammatory baved disease, and does not have a first degree relative such as pancreatic cancer, systemic solerosis or CLL imply affection and treatment of early-stage cancer and detection The degree to which each of these mechanisms contributes to a reduction in mortality is unknown, although it is likely any screening program that reduces mortality from colorectal cancer.**** ** Sevening for colorectal cancer US Preventive Services Task Force Recommendation Statement. JAMA Jun 21, 2016; 315(23):2564-2575 *********************************	Gene Expre dens ANXA3* (AC) CLEC4D* (AC) TNFAIP6* (AC) LMNB1* (AC) PRRG4* (AC) VIN1* (AC) UN11* (AC) ULXB8 (C) * Ülferinte wither negret to and removal of denome r. Colonoscopy is a nec 2875	ssion rdb Threshold 1.9 2.5 1.8 1.8 0.9 1.5 24.5 LI2R8 sory of benign e of conditions malous polyps, in in colorectal sessary step in

#### Disclaimer

This test is not recommended for patients that have previous history of colorectal cancer, or pre-cancerous (e.g. adenomatous) polyps, or familial or inherited colon polyp syndromes, or inflammatory bowel disease, or have received chemotherapy and/or radiation.				
Page 1	©2019 Sta	Dr. Leroy D. Mell, Jr.   Laboratory Director   CLIA No. 49D2059683   NPI No. 1962846790 geZero Life Sciences   8751 Park Central Drive, Suite 200   Richmond, VA 23227   www.StageZeroLifeSciences.com	Rpt ver: SZLS 1.0 Ref ver: 2.0 Source:	

#### **TEST INTERPRETATION**

- If the ColonSentry score is elevated, there is an increased probability of the patient having colorectal cancer.(1-2)
- Patients with elevated ColonSentry scores should be encouraged to have a colonoscopy.
- Patients with average ColonSentry scores should continue to comply with USPSTF guidelines.

# Contact Us Today to Learn More 1-855-420-7140

clientrelations@stagezerols.com



- 1. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006 Mar; 147(3):126-32.
- 2. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010 Mar 1;126(5):1177-86.
- 3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\*Stat Database: Cancer Stat Facts: Colorectal Cancer, National Cancer Institute, DCCPS, Surveillance Research Program, released December 2018. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
- 4. Chao S, Ying J, Liew G, et al. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case- control study. J Exp Clin Cancer Res. 2013 Jul 23;32:44.
- 5. Yip KT, Das PK, Suria D, et al. A case- controlled validation study of a blood- based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res. 2010 Sep 16;29:128
- 6. Han M, Liew CT, Zhang HW, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res. 2008 Jan 15;14(2):455-60.
- 7. Moghadamyeghaneh Z, Alizadeh RF, Phelan M, et al. Trends in Colorectal Cancer Admissions and Stage at Presentation-Impact of Screening. Surgical endoscopy. 2016;30(8):3604-3610. doi:10.1007/s00464-015-4662-3.
- 8. Chao S, Pilcz T, Stamatiou, D, et al. Stability of The ColonSentry® Colon Cancer Risk Stratification Test. Int J of Dis Markers. 2019 DOI: 10.29011/JDM -101. 100001